University of Vermont heads translatlantic cardiovascular research network

December 13, 2004

BURLINGTON, Vt. - A new $6 million grant will help researchers at the University of Vermont College of Medicine direct an innovative transatlantic network linking scientists who study blood-clotting disorders at three U.S. and three European universities.

The five-year grant is among the first four Transatlantic Networks of Excellence in Cardiovascular Research to be funded by Fondation Leducq, a French institution that supports European-American collaborations in cardiovascular research. Edwin Bovill, M.D., professor and chair of pathology at the University of Vermont College of Medicine and an international expert in the field of blood-clotting disorders - known as thrombosis - is leader of the project.

Titled the Leducq International Network Against Thrombosis, the project's member institutions in the U.S. include the University of Vermont, the University of Washington, and the Oklahoma Medical Research Institute at the University of Oklahoma; and in Europe, the University of Leiden (The Netherlands), the University of Leuven (Belgium), and the University of Paris (France). Each institution specializes in a different, yet related, aspect of research on the role of thrombosis in arterial and venous vascular disease. According to Bovill, the focus of the grant is to encourage the exchange of ideas between institutions engaged in similar research and to facilitate faculty and students spending research time at the different institutions.

"Like all research studies, this program is a bit of an experiment," said Bovill, who also serves as U.S. coordinator for the project. "The grant will allow us to more effectively support what we have already been doing, which we hope will lead to the establishment of a sustainable model that amplifies the amount of scientific training and discovery taking place."

On December 10 through 12, 54 representatives from the institutions in the network gathered in Burlington, Vermont, to present data from their current studies and discuss which research, technology and facilities will be used for LINAT.
In addition to Bovill, site leaders in the project include European coordinator Frits Rosendaal, M.D., Ph.D., Leiden University; Bruce Psaty, M.D., Ph.D., University of Washington; Chuch Esmon, Ph.D., Oklahoma Medical Research Institute; Roger Lignen, Ph.D., University of Leuven; and Martine Aiach, Ph.D., University of Paris. For more information about Fondation Leducq, go to

University of Vermont

Related Thrombosis Articles from Brightsurf:

Early indications of thrombosis help in preventing postoperative complications
It is well-known that surgeries can be complicated by life-threatening thromboses that are hard to predict and not easy to prevent.

Standalone D-dimer test strategy may simplify diagnosis of deep vein thrombosis
New research suggests that it may be possible to simplify the diagnosis of deep vein thrombosis (DVT) without compromising accuracy.

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

High risk of deep vein thrombosis and pulmonary embolism in patients with COVID-19
In a systematic review of the worldwide published data on ''Venous thromboembolism (VTE) in COVID-19 patients'', researchers from the Department of Medicine I (MedUni Vienna), provide an in-depth analysis on the risk of VTE in patients hospitalised for COVID-19.

Possible blood-clotting mechanism in COVID-19 found
Why so many COVID-19 patients get blood clots (thrombosis) remains uncertain.

What is cerebral venous thrombosis? study finds blood clot condition on the rise
Cerebral venous thrombosis (CVT) occurs when a blood clot forms in one of the veins in the brain, preventing blood from draining out of the brain.

Late coronary stent thrombosis in patient with COVID-19
This case report describes a patient with COVID-19 who developed late drug-eluting stent thrombosis.

EULAR 2020: Thrombosis risk particularly high for people suffering
People suffering from rheumatoid arthritis with increased disease activity are more often affected by thrombosis.

Venous thrombosis among critically ill patients with COVID-19
A systematic assessment of deep vein thrombosis among patients in an intensive care unit in France with severe COVID-19 is reported in this case series.

Miniature version of human vein allows study of deep vein thrombosis
The Vein-Chip device, a miniaturized version of a large human vein, allowed scientists to study changes in vein wall cells, blood flow and other functions that lead to deep vein thrombosis in humans.

Read More: Thrombosis News and Thrombosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to